Eisai Gets U.S. DEA Clearance To Market Obesity Drug After Year's Delay
This article was originally published in PharmAsia News
Executive Summary
Eisai's Belviq (lorcarserin) weight-loss drug has received marketing clearance by the U.S. Drug Enforcement Agency, which downgraded its abuse risk level after a year-long review.